About Hemato

Aims

Hemato (ISSN 2673-6357) publishes regular research papers, reviews, letters and communications covering all aspects of hematology, from pathogenesis to diagnosis and personalized management, through in vivo genomic and immunologic research. Our aim is to improve the study of clinical and basic research of blood-related diseases. It covers topics related to hematopathology from laboratory to clinical studies, and the prevention, diagnosis, and therapeutics of hematological diseases, including components such as blood cells, blood proteins, blood vessels, bone marrow and coagulation. Furthermore, it encompasses topics related to all blood diseases, such as blood cancers, bleeding disorders, and hemophilia. There is no restriction on the length of the papers or colors used. The method/approach must be presented in detail so that the results can be reproduced. There are, in addition, three unique features of this journal: 

  • Manuscripts regarding research proposals and research ideas are welcome
  • Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material
  • We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds

Scope

  • Non neoplastic blood disorders
  • Myeloid leukemias
  • Lymphoid leukemias
  • Acute leukemias
  • Chronic leukemias
  • Lymphomas
  • Hodgkin lymphomas
  • Non Hodgkin lymphomas
  • Virus-associated lymphomas
  • HIV-associated lymphomas
  • Immunodeficiency-associated lymphomas
  • Molecular epidemiology
  • Immunobiology
  • Immunogenetics
  • Genomics
  • Immunotherapy
  • Transplantation
  • Target therapy
  • Basket trials
  • Confirmatory research studies

MDPI Publication Ethics Statement

Hemato is a member of the Committee on Publication Ethics (COPE). MDPI takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, inappropriate authorship credit, and the like, do arise. MDPI takes such publishing ethics issues very seriously and our editors are trained to proceed in such cases with a zero tolerance policy. To verify the originality of content submitted to our journals, we use iThenticate to check submissions against previous publications. MDPI works with Publons to provide reviewers with credit for their work.

Book Reviews

Authors and publishers are encouraged to send review copies of their recent related books to the following address. Received books will be listed as Books Received within the journal's News & Announcements section.

MDPI
St. Alban-Anlage 66
CH-4052 Basel
Switzerland
 
E-mail:

Copyright / Open Access

Articles published in Hemato will be Open-Access articles distributed under the terms and conditions of the Creative Commons Attribution License (CC BY). The copyright is retained by the author(s). MDPI will insert the following note at the end of the published text:

© 2021 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

Reprints

Reprints may be ordered. Please contact for more information on how to order reprints.

Announcement and Advertisement

Announcements regarding academic activities such as conferences are published for free in the News & Announcements section of the journal. Advertisement can be either published or placed on the pertinent website. Contact e-mail address is .

Editorial Office

Dr. Carey Yuan
Managing Editor

For further MDPI contacts, see here.

Back to TopTop